Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Leukemia & Lymphoma|January 11, 2019
Adoptive cell therapy for acute myeloid leukemiaHongbing Ma, Swaminathan Padmanabhan Iyer, Simrit Parmar, et al.
Case Reports in Hematology|June 20, 2019
Complete Response to R-EPOCH in Primary Cardiac LymphomaKartik Anand, Sai Ravi Pingali, Barry Trachtenberg, et al.
The Journal of Biological Chemistry|August 18, 2012
The transcription factor Wilms tumor 1 confers resistance in myeloid leukemia cells against the proapoptotic therapeutic agent TRAIL (tumor necrosis factor α-related apoptosis-inducing ligand) by regulating the antiapoptotic protein Bcl-xLHima Bansal, Theresea Seifert, Carlos Bachier, et al.
Cancer|March 27, 2015
Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myelomaRuth Seggewiss-Bernhardt, Ralf C Bargou, Yeow Tee Goh, et al.
Investigational New Drugs|December 20, 2013
Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemiaKevin R Kelly, Thomas C Shea, André Goy, et al.
Cancer Chemotherapy and Pharmacology|August 17, 2013
Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemiasIvana Gojo, Mariola Sadowska, Alison Walker, et al.
Journal of Hematology & Oncology|January 25, 2014
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responsesBertrand Coiffier, Barbara Pro, H Miles Prince, et al.
Leukemia & Lymphoma|July 9, 2016
Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapyRoxanne C Jewell, Thomas J Kipps, Jan Dürig, et al.
British Journal of Haematology|September 17, 2013
A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphomaBertrand Coiffier, John Radford, André Bosly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS StudyLaurie H Sehn, Andre Goy, Fritz C Offner, et al.
Pageof 2